Ovarian Cancer

Robert W. Holloway, MD, and Chad A. Hamilton, MD, provide clinical pearls for community physicians using maintenance therapies for ovarian cancer.

Key opinion leaders discuss how they decide between two regimens for ovarian cancer maintenance therapies.

Experts review the potential maintenance therapy approaches for a 64-year-old woman with stage IIIC high-grade serous ovarian cancer.

Dr. Chad Hamilton explains pivotal data from several important clinical trials in ovarian cancer.

Debra L. Richardson, MD, FACS, FACOG, discusses the rationale for the ongoing phase 3 UPNEXT trial in platinum-sensitive ovarian cancer.

Alexander Babatunde Olawaiye, MD, discusses factors that influence optimized frontline maintenance therapy in advanced ovarian cancer.

In patients with ovarian cancer and pretreatment elevated CA-125 who achieved remission after frontline therapy, most recurrences are detected by rising CA-125 levels or symptoms.

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Amer Karam, MD, discusses determining whether to use debulking surgery after recurrence in ovarian cancer.

Jubilee Brown, MD, discusses recent developments and upcoming trials exploring minimally invasive surgery in ovarian cancer.

Robert W. Holloway, MD, details how he decides to start maintenance therapy after first-line ovarian cancer treatments.

Chad A. Hamilton, MD, and Robert W. Holloway, MD, review the case of a 57-year-old woman with stage IIIA high-grade epithelial ovarian cancer.

The FDA has granted a fast track designation to CX-5461 (Pidnarulex) as a potential therapeutic option for patients with breast and ovarian cancers that harbor BRCA1/2, PALB2, or other homologous recombination deficiency mutations.

David M. Gershenson, MD, discusses the results of the phase 3 MILO trial in low-grade serous ovarian cancer.

Oncologists debate the need for genetic counseling for ovarian cancer patients and how to approach molecular testing alongside neoadjuvant chemotherapy.

Dr Robert W. Holloway explains his typical approach to ovarian cancer biomarker testing and sequencing.

Nivolumab did not significantly improve overall survival compared with chemotherapy in Japanese patients with platinum-resistant ovarian cancer.

The FolRα-targeted antibody-drug conjugate STRO-002 was found to elicit encouraging responses in heavily pretreated patients with advanced ovarian cancer.

Molecular testing is an established and essential precursor to treatment for patients with non–small cell lung cancer based on the volume of actionable targets, such as EGFR and KRAS G12C mutations, as well as PD-L1 status.

Bradley J. Monk, MD, FACS, discusses the emergence and utility of NaPi2b as a target in ovarian cancer.

Richard Penson, MD, MBBS, discusses how he makes treatment decisions for maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer.

Anil K. Sood, MD, provides insight into his approach toward the frontline maintenance treatment of women with advanced ovarian cancer.

Chad A. Hamilton, MD, and Robert W. Holloway, MD, discuss challenges clinicians face in treating ovarian cancer and review the current state of biomarker testing.

Anil K. Sood, MD, discusses navigating frontline maintenance therapy in ovarian cancer.

Richard T. Penson, MD, MRCP, discusses selecting between PARP inhibitors for switch maintenance therapy in recurrent ovarian cancer.

Britt Erickson, MD, discusses the toxicity profiles of available PARP inhibitors used in the treatment of patients with ovarian cancer. 

Stephen L. Rose, MD, UW Health, discusses the importance of genetic testing in ovarian cancer.

Premal Thaker, MD, MS, discusses the importance of surveying patients on unmet needs in ovarian cancer. 

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

First-line maintenance treatment with the PARP inhibitor niraparib yielded a clinically meaningful and statistically significant improvement in progression-free survival vs placebo in Chinese patients with platinum-responsive advanced ovarian cancer, regardless of biomarker status, according to data from the phase 3 PRIME trial.